Carlyn Tan

39PUBLICATIONS
181CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene expression (incl. microarray and other genome-wide approaches)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Jul 29, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

|Jun 17, 2026
Practical Management of Bispecific Antibodies in Multiple Myeloma.

|Jun 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry.

|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

|May 01, 2026
A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

Pageof 7

Frequent Collaborators

27 joint publications

Neha Korde

27 joint publications

Urvi Shah

25 joint publications

Malin L Hultcrantz

24 joint publications

Heather Landau